trending Market Intelligence /marketintelligence/en/news-insights/trending/t0fsd69hdqx8j_-knqh6a2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Gates Foundation to advance HIV prevention with $140M investment

IFRS 9: Time is Running Out for Insurance Companies to Comply

5 Quant Research Traps to Avoid

S&P Global Market Intelligence

Wind Power by the Numbers: U.S., Canada and Mexico

CUSIP Identifier Requests for New U.S. Corporate Debt Surge in January

Gates Foundation to advance HIV prevention with $140M investment

The Bill & Melinda Gates Foundation is investing up to $140 million in Intarcia Therapeutics Inc. as part of an effort to combat HIV.

Intarcia Therapeutics is developing an anti-HIV vaccine that would be administered annually or semi-annually in sub-Saharan Africa and other countries where the epidemic is most severe.

The company attracted funding from the Gates Foundation during its second series EE equity financing which yielded $206 million in proceeds.

The Gates Foundation committed $50 million during the financing and has agreed to pay up to a further $90 million in milestone-related payments to the HIV vaccination.